Lucia and Alberto Giovanni Aleotti: "A heartfelt choice for our country". The new plant will be 40.000 square meters and will employ 250 direct people and as many in the related industries.
Menarini chooses Italy for its new 150 million euro factory. It will not only be a beautiful factory, even if it will be the most modern and one of the largest of the Group born in 1886 in a Neapolitan pharmacy, the Menarini International Pharmacy, but it will mark Italy's desire to start running again.
The choice to stop the search for the most economically attractive international location, and the decision to favor Italy, in fact came about during the dramatic days of the lockdown, when the tragic consequences of the pandemic on the Italian economy began to be evident: "We made a heartfelt decision, shared with the Board of Directors: to privilege our country, and do it immediately, with an investment of 150 million that immediately makes a contribution to the economy and employment”They commented Lucia and Alberto Giovanni Aleotti, shareholders and members of the Menarini Board. "We are an Italian company and we are proud of it. Here we will produce drugs that are the essence of the Menarini Group, used every day by tens of millions of patients in Italy and abroad.".
The site will be built in the Florentine area, will occupy 40.000 square meters and will employ 250 direct people and as many in the related industries. It will be a smart manufacturing plant, with innovative production technologies and automation and digitalization systems in line with the Industry 4.0 program with important environmental sustainability objectives. The plant will have an annual production capacity of approximately 100 million packs corresponding to approximately 3 billion tablets and will bear the will to relaunch it, thanks to a particular initiative: "Qhis establishment will have a name, a bit like a child - continue Lucia and Alberto Giovanni Aleotti - Our employees will choose it. A name that summarizes the courage, the will and the heart of Italy that wants to get up and team up in the most difficult moments".
The Menarini Group, which recently announced the purchase offer on the US biotech Stemline, closed 2019 with growing accounts compared to 2018. The turnover is close to 3 billion and 800 million euros (3.793 million), up by 3,2% compared to 2018, and the EBITDA is 492 million. Growth was driven by international markets despite the patent expiry of Adenuric (febuxostat), a drug for hyperuricemia. "The year that ended was obviously not affected by the Covid crisis, and saw Menarini increase its presence abroad and strengthen its governance with the appointment, in September, of the Group's CEO, Elcin Barker Ergun. Today the international turnover is 77% of the total thanks to the dedication and commitment of our employees who bring the quality of Menarini drugs to the world", commented Eric Cornut, president of the Menarini Group.